Open AccessEffective Tacrolimus Treatment for Patients with Non-Severe Aplastic Anemia That is Refractory/Intolerant to Cyclosporine A: A Retrospective Study
Author(s) -
Yali Du,
Yuzhou Huang,
Wen Zhou,
Xinjian Liu,
Fangfei Chen,
Chen Yang,
Miao Chen,
Jing Ruan,
Bing Han
Publication year - 2020
Publication title -
drug design, development and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.964
H-Index - 64
ISSN - 1177-8881
DOI - 10.2147/dddt.s275975
Subject(s) - tacrolimus , medicine , aplastic anemia , gastroenterology , refractory (planetary science) , hematopoietic stem cell transplantation , creatinine , transplantation , calcineurin , anti thymocyte globulin , salvage therapy , retrospective cohort study , chemotherapy , bone marrow , physics , astrobiology
For symptomatic non-severe aplastic anemia (NSAA) patients who cannot afford anti-thymocyte globulin (ATG) or allogeneic hematopoietic stem cell transplantation (HSCT), tacrolimus (FK) may be an option if these patients do not respond or become tolerant to cyclosporine A (CsA).